<DOC>
	<DOCNO>NCT00354744</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , vincristine , irinotecan , ifosfamide , etoposide , doxorubicin , cyclophosphamide , dactinomycin , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Giving high-dose combination chemotherapy together radiation therapy may kill tumor cell . PURPOSE : This phase III trial study well give high-dose combination chemotherapy together radiation therapy work treat patient newly diagnose metastatic rhabdomyosarcoma ectomesenchymoma .</brief_summary>
	<brief_title>High-Dose Combination Chemotherapy Radiation Therapy Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma Ectomesenchymoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Improve early disease control interval patient newly diagnose , high-risk , metastatic rhabdomyosarcoma ectomesenchymoma use intensive , interval-compression therapy ( comprise vincristine , irinotecan hydrochloride , ifosfamide , etoposide , doxorubicin hydrochloride , cyclophosphamide , dactinomycin ) permit maximal early exposure know effective agent . - Determine feasibility concurrent irinotecan hydrochloride radiotherapy patient . - Assess immediate- short-term side effect concurrent irinotecan hydrochloride radiotherapy patient . Secondary - Expand available data response irinotecan hydrochloride vincristine previously untreated patient high-risk rhabdomyosarcoma . - Evaluate , prospectively , validate gene expression value intent define best diagnostic predictor powerful prognostic classifier . OUTLINE : This prospective , nonrandomized , multicenter study . Patients stratify accord prognostic factor predictive outcome ( e.g . histology , bone/bone marrow involvement , number metastatic site ) . Patients receive high-dose chemotherapy comprise vincristine IV 1 minute day 1 week 1-5 , 7 , 8 , 11 , 12 , 15 , 16 , 20-24 , 28 , 29 , 32 , 33 , 35 , 38 , 41-44 , 47 , 48 , 50 , 51 ; irinotecan hydrochloride IV 1 hour day 1-5 week 1 , 4 , 20 , 23 , 47 , 50 ; ifosfamide IV 1 hour etoposide IV 30-60 minute day 1-5 week 9 , 13 , 17 , 26 , 30 . Patients also receive doxorubicin hydrochloride IV continuously 24 hour day 1 2 week 7* , 11 , 15 , 28 , 32 ; cyclophosphamide IV 30-60 minute day 1 week 7 , 11 , 15 , 28 , 32 , 35 , 38 , 41 , 44 ; dactinomycin IV 1-5 minute day 1 week 35 , 38 , 41 , 44 absence disease progression unacceptable toxicity . Patients also receive filgrastim ( G-CSF ) subcutaneously week 7-9 , 11-13 , 15-17 , 22 , 26 , 28-30 , 32 , 33 , 35 , 38 , 41-44 begin 24-36 hour last chemotherapy dose continue blood count recover . NOTE : *Patients undergo early radiotherapy intracranial extension receive doxorubicin week 7 . Beginning week 20 ( week 1 patient parameningeal tumor intracranial extension [ spinal cord compression ] require emergency radiotherapy ) , patient also undergo radiotherapy day , 5 day week , approximately 5½ week . Some patient may also undergo second-look surgery . After completion study treatment , patient follow periodically ≥ 10 year . PROJECTED ACCRUAL : A total 75 patient accrue study .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Dactinomycin</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm highrisk rhabdomyosarcoma ectomesenchymoma Prior enrollment COGD9902 confirm local histological diagnosis require Tissue must submit pathologic review within 2 day patient registration COGD9902 Newly diagnose disease Metastatic disease ( stage IV , clinical group IV ) Has undergone initial surgical procedure ( include biopsy ) provide definitive diagnosis within past 42 day Parameningeal paraspinal tumor allow Patients parameningeal ( without intracranial extension [ ICE ] ) paraspinal tumor begin study chemotherapy week 1 radiotherapy week 20 Patients evidence ICE , define contrast MRI show primary tumor touch , displaces , invades , distorts , otherwise cause signal abnormality dura contiguity primary site brain spinal cord , eligible ICE presume exist cerebrospinal fluid cytopathology positive tumor diagnosis Patients require emergency radiotherapy eligible Patients require emergency radiotherapy ( intracranial extension spinal cord impingement ) begin study chemotherapy week 1 ( irinotecan hydrochloride vincristine ) concurrently radiation therapy PATIENT CHARACTERISTICS : ECOG Zubrod performance status ( PS ) 02 ( Lansky PS 50100 % patient &lt; 10 year age Karnofsky PS 50100 % patient ≥ 10 year age ) Absolute neutrophil count ≥ 750/mm³* Platelet count ≥ 75,000/mm³* Creatinine clearance radioisotope glomerular filtration rate ≥ 70 mL/min ( ≥ 40 mL/min infant &lt; 1 year age ) Patients urinary tract obstruction tumor must meet renal function criterion list AND must unimpeded urinary flow establish via decompression obstruct portion urinary tract SGPT &lt; 2.5 time normal Bilirubin &lt; 1.5 mg/dL Shortening fraction ≥ 27 % echocardiogram OR ejection fraction ≥ 50 % MUGA Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception study ≥ 1 month study completion No evidence uncontrolled infection Able undergo radiotherapy NOTE : *Abnormal blood count allow bone marrow biopsy aspirate proven bone marrow involvement rhabdomyosarcoma PRIOR CONCURRENT THERAPY : No prior chemotherapy except steroid No prior radiotherapy No concurrent aprepitant ifosfamide doxorubicin hydrochloride chemotherapy No concurrent dexrazoxane No concurrent sargramostim ( GMCSF ) pegfilgrastim</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>adult rhabdomyosarcoma</keyword>
	<keyword>previously untreated childhood rhabdomyosarcoma</keyword>
	<keyword>adult malignant mesenchymoma</keyword>
	<keyword>childhood malignant mesenchymoma</keyword>
	<keyword>metastatic childhood soft tissue sarcoma</keyword>
	<keyword>stage IV adult soft tissue sarcoma</keyword>
</DOC>